Shunian He, MD
Internal Medicine · Marlborough, MANPI 1740207471
Payments from drug & device makers
Across 429 payments — averaging $18.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$1K
- Novo Nordisk$836
- Pfizer$573
- Lilly USA, LLC$553
- Sanofi-aventis U.S. LLC$407
- plus $3K from 31 others
What the payments were for
- Food & beverage$8,148100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 73 | $1,237 |
| AstraZeneca(2 entities) | 65 | $1,227 |
| Novo Nordisk | 45 | $836 |
| Pfizer | 29 | $573 |
| Lilly USA, LLC | 27 | $553 |
| Sanofi-aventis U.S. LLC | 24 | $407 |
| Johnson & Johnson | 16 | $347 |
| Merck | 15 | $277 |
| Bayer | 13 | $255 |
| GSK | 11 | $195 |
| Lundbeck LLC | 7 | $175 |
| Otsuka America Pharmaceutical, Inc. | 8 | $171 |
| Amgen | 8 | $171 |
| Exact Sciences | 8 | $168 |
| Amarin Pharma, Inc. | 9 | $161 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $156 |
| E.r. Squibb & Sons, L.L.C. | 8 | $141 |
| Boehringer Ingelheim | 6 | $137 |
| Novartis | 8 | $135 |
| Phathom Pharmaceuticals, Inc. | 5 | $115 |
| Ardelyx, Inc. | 4 | $89 |
| Corium, LLC | 4 | $83 |
| Idorsia Pharmaceuticals US Inc | 3 | $71 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $62 |
| Abbott | 3 | $59 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $58 |
| Orexo US, Inc. | 3 | $53 |
| Teva Pharmaceuticals USA, Inc. | 3 | $43 |
| Vanda Pharmaceuticals Inc. | 1 | $30 |
| Axsome Therapeutics, Inc. | 1 | $29 |
| Sanofi Pasteur Inc. | 2 | $25 |
| Indivior Inc. | 1 | $22 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Ironwood Pharmaceuticals, Inc | 1 | $20 |
| Lucid Diagnostics Inc. | 1 | $18 |
| Dexcom, Inc. | 1 | $16 |
| Biodelivery Sciences International, Inc. | 1 | $12 |
How this compares
$8,148 in reported general payments places this provider in the 90th percentile of 4,983 internal medicine providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 58 | $58,604 |
| OzempicSemaglutide | 34 | $49,355 |
| XareltoRivaroxaban | 28 | $42,114 |
| TrulicityDulaglutide | 38 | $41,309 |
| FarxigaDapagliflozin Propanediol | 23 | $36,203 |
| RybelsusSemaglutide | 21 | $32,660 |
| Nurtec OdtRimegepant Sulfate | 16 | $28,041 |
| JanuviaSitagliptin Phosphate | 17 | $25,585 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 11 | $24,820 |
| JardianceEmpagliflozin | 14 | $21,298 |
| MounjaroTirzepatide | 16 | $15,761 |
| LinzessLinaclotide | 19 | $14,877 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 15 | $13,353 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $8,520 |
| Atorvastatin Calcium | 557 | $7,478 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6 | $836 | $106,83566 claims |
| PfizerEliquis, Nurtec Odt | $573 | $86,64674 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $553 | $57,06954 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,227 | $47,57450 claims |
| Johnson & JohnsonXarelto | $347 | $42,11428 claims |
| MerckJanuvia, Janumet | $277 | $32,71129 claims |
| Boehringer IngelheimJardiance | $137 | $21,29814 claims |
| AbbVieLinzess | $1,237 | $14,87719 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $407 | $13,35315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,983 internal medicine providers in Massachusetts.
Other internal medicine in Marlborough
- Monzurul ChowdhuryMarlborough$3.5M
- Marguerite BrackleyMarlborough$613K
- Noopur RajeBoston$19.9M
- Michael McCartneyNewburyport$17.6M
- Rebecca HeistBoston$17.4M
- Richard PlattBoston$13.5M
- Ryan CorcoranBoston$11.4M
- Joyce LiuCharlestown$10.3M
- Elizabeth LeeBoston$9.8M
- Adnan DahdulSpringfield$8.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.